Table 2.
Mean ALT activity for treatment groups in identified randomized controlled trials. Study subjects were ethanol users who were administered acetaminophen or placebo. Shaded areas show measurements obtained during administration of acetaminophen, unshaded those either at baseline, or after acetaminophen administration had ended.
| Study | Day | N | Placebo | Acetaminophen | |
|---|---|---|---|---|---|
| Mean (SD) | N | Mean (SD) | |||
| Kuffner9 | 0 | 98 | 36.5 (20.3) | 101 | 34.5 (19.3) |
| 2 | 95 | 37.3 (23.9) | 101 | 32.9 (22.0) | |
| 4 | 96 | 41.9 (33.9) | 98 | 40.2 (31.1) | |
| Heard8 | 0 | 52 | 22.9 (8.4) | 104 | 21.4 (7.5) |
| 4 | 51 | 22.1 (8.8) | 102 | 21.1 (7.5) | |
| 11 | 50 | 21.6 (7.9) | 100 | 30.0 (18.6) | |
| Kuffner10 | 0 | 137 | 46.7 (36.6) | 306 | 49.4 (38.2) |
| 2 | 129 | 45.3 (33.6) | 282 | 45.7 (38.6) | |
| 3 | 123 | 46.7 (37.1) | 269 | 45.9 (36.6) | |
| 4 | 120 | 50.5 (42.1) | 262 | 49.0 (39.2) | |
| 5 | 119 | 54.9 (47.5) | 256 | 57.1 (45.2) | |
| Parra11 (2g) | 0 | 12 | 37.3 (10.2) | 12 | 32.3 (12.8) |
| 14 | 12 | 36.9 (11.3) | 12 | 45 (9) | |
| 28 | 12 | 34.5 (11) | 12 | 36.5 (10.9) | |
| Parra11 (4g) | 0 | * | 12 | 37.3 (10.2) | |
| 14 | * | 12 | 55.2 (30) | ||
| 28 | * | 12 | 36.5 (9.8) | ||
| Bartels6 | 0 | 22 | 38.7 (24.8) | 23 | 32.9 (20.8) |
| 1 | 21 | 38.8 (24.3) | 23 | 34.3 (23.2) | |
| 2 | 20 | 40.6 (21.0) | 22 | 34.4 (25.6) | |
| 3 | 19 | 42.1 (22.8) | 21 | 37.3 (25.6) | |
| 4 | 17 | 47.2 (27.8) | 17 | 44.8 (34.7) | |
| Dart7 | 0 | 68 | 47.2 (32.6) | 74 | 48.2 (36.9) |
| 2 | 68 | 41.9 (27.3) | 71 | 41.9 (33.9) | |
| 4 | 65 | 44.1 (37.5) | 68 | 47.2 (41.9) | |
| 6 | 64 | 49.3 (42.1) | 66 | 55.9 (44.8) | |
| 7 | 64 | 49.2 (42.4) | 66 | 61.8 (50.4) | |
*
Parra11 compared placebo to 2g/day and 4/g day. Shaded areas show measurements obtained during administration of acetaminophen, unshaded those either at baseline, or after acetaminophen administration had ended.